• I-BET151 (GSK1210151A): Technical Guidance for BET Inhibitio

  2026-04-22

  I-BET151 (GSK1210151A) is a selective BET bromodomain inhibitor designed to disrupt BRD2, BRD3, and BRD4-driven transcriptional programs, supporting cancer biology and mechanistic studies such as apoptosis and cell cycle arrest assays. It should be used where precise, targeted BET inhibition is required, and is not suitable for diagnostic or medical applications.

• BGJ398 (NVP-BGJ398): Advancing Functional Assays in FGFR Res

  2026-04-22

  Explore how BGJ398 (NVP-BGJ398) elevates FGFR-driven malignancies research by enabling precision functional assays and developmental biology insights. Uncover protocol guidance, cross-species mechanistic findings, and unique experimental perspectives.

• Mifepristone (RU486): Applied Workflows in Cancer and Reprod

  2026-04-21

  Mifepristone (RU486) offers scientists precision control over progesterone signaling, unlocking advanced workflows in oncology and reproductive biology. This guide delivers actionable protocol enhancements, troubleshooting strategies, and evidence-backed applications, setting a new standard for translational research with APExBIO’s trusted reagent.

• EdU Imaging Kits (HF594): Advancing Cell Proliferation Assay

  2026-04-21

  EdU Imaging Kits (HF594) leverage click chemistry for sensitive DNA synthesis detection, enabling robust cell proliferation assays with minimal background. This article details optimized workflows, comparative advantages, and troubleshooting strategies, anchored by recent mechanistic insights in Treg cell biology and asthma research.

• Cy7 NHS Ester: Protocols and QC for NIR Protein Labeling

  2026-04-20

  Cy7 NHS ester (SKU A8109) is a sulfonated, highly water-soluble near-infrared dye designed for efficient and reproducible labeling of amino groups on proteins and peptides. This reagent is best suited for in vitro and in vivo applications requiring minimal protein denaturation and strong signal-to-background ratios in near-infrared fluorescent imaging. It is not optimal for workflows requiring long-term storage of dye solutions or labeling in highly organic solvents.

• Magnetic Bispecific Nano-antibodies Enable In Vivo CAR-T Mim

  2026-04-20

  This study introduces a novel magnetic bispecific nano-antibody platform (M-BiNanoAb) that enables the in vivo reprogramming and magnetic guidance of CAR-T-mimicking effector cells for solid tumor therapy. The findings suggest a promising, less invasive alternative to ex vivo CAR-T engineering, with enhanced tumor infiltration and cytotoxicity against PDL1-positive cancers.

• Precision Apoptosis Detection: Caspase-3 Assays in Translati

  2026-04-19

  This thought-leadership article explores the mechanistic significance of caspase-3 as a cysteine-dependent aspartate-directed protease in apoptosis, critically evaluates the APExBIO Caspase-3 Colorimetric Assay Kit for translational workflows, and offers strategic guidance for researchers bridging basic insights and clinical innovation. Drawing on recent immunology findings, including the role of ER stress and inflammation in macrophage apoptosis, this piece integrates protocol parameters, competitive benchmarking, and an outlook focused on disease modeling and therapeutic discovery.

• Streptavidin-Cy3: Precision Biotin Detection in IHC & IF Wor

  2026-04-18

  Streptavidin-Cy3 conjugates enable ultra-sensitive, stable, and bright detection of biotinylated biomolecules across immunohistochemistry, immunofluorescence, and flow cytometry. This guide translates cutting-edge research into practical, reproducible protocols and troubleshooting strategies for maximizing assay clarity and sensitivity.

• iPSC-Based Prescreening Platform for Ultrarare Disease Thera

  2026-04-17

  This study introduces a patient-specific induced pluripotent stem cell (iPSC) platform designed to evaluate drug efficacy and safety in individuals with ultrarare, previously uncharacterized pathogenic mutations. The approach enables personalized clinical trial selection, offering a significant advance in precision medicine for rare mitochondrial disorders such as Leigh-like syndrome.

• Co-Targeting BRD4 and RAC1 Disrupts c-MYC/G9a Axis in Breast

  2026-04-16

  This study demonstrates that simultaneous inhibition of BRD4 and RAC1 suppresses growth, stemness, and tumorigenesis across breast cancer subtypes by disrupting the c-MYC-G9a-FTH1 axis and downregulating HDAC1. The findings elucidate an epigenetic vulnerability in breast tumors, highlighting new avenues for mechanistic research and targeted intervention.

• Amiloride (MK-870): Precision Tools for Sodium Channel Resea

  2026-04-15

  Amiloride (MK-870) enables targeted dissection of epithelial sodium channels and uPAR signaling, driving advances in ion transport and disease modeling. This article delivers workflow optimization, troubleshooting insights, and practical guidance for leveraging APExBIO's Amiloride in high-impact sodium channel research.

• Co-Targeting BRD4 and RAC1 Disrupts c-MYC/G9a Axis in Breast

  2026-04-14

  This study uncovers how simultaneous inhibition of BRD4 and RAC1 suppresses breast cancer growth and stemness by disrupting the c-MYC-G9a-FTH1 signaling axis and modulating HDAC1-mediated chromatin states. The findings reveal a promising combinatorial epigenetic strategy for targeting diverse molecular subtypes of breast cancer.

• SP2509: Precision Epigenetic Modulation in AML Research

  2026-04-13

  SP2509, a potent Lysine-specific demethylase 1 antagonist from APExBIO, is redefining the frontiers of cancer epigenetics, particularly in acute myeloid leukemia (AML). This thought-leadership article delivers deep mechanistic insights, concrete experimental validation, and strategic guidance for translational researchers aiming to harness SP2509’s full potential in apoptosis induction and differentiation of AML cells. By contextualizing SP2509 within the broader landscape of chromatin-targeted therapies and drawing parallels to advanced combinatorial approaches in solid tumors, we map the path for next-generation epigenetic interventions.

• Annexin V for Apoptosis Assays: Advanced Protocols & Insight

  2026-04-13

  Harness the precision of APExBIO’s Annexin V, human recombinant for sensitive apoptosis detection and immune cell research. Discover protocol optimizations, real-world troubleshooting, and workflow enhancements that extend from immune tolerance modeling to high-throughput cell death analysis.

• Thioguanine in Research: Optimizing Antitumor and Antiviral

  2026-04-12

  Thioguanine (6-thioguanine) stands out as a dual-action compound for both cancer cell proliferation inhibition and EV71 virus inhibition, leveraging precise DNMT1 inhibition mechanisms. This article delivers protocol-driven guidance, highlights nanoparticle-enabled enhancements, and translates cutting-edge findings into actionable troubleshooting strategies for oncology and virology labs.

11436 records 1/763 page Next 12345 下5页 Last page